Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Severe interstitial pneumonia caused by cetuximab: a case report and review of the literature

Severe interstitial pneumonia caused by cetuximab: a case report and review of the literature Cetuximab is an IgG1 chimeric mAb against epidermal growth factor receptor, which can be used for chemotherapy failure or tolerance in patients with epidermal growth factor receptor expressed RAS wild-type metastatic colorectal cancer. We report on a patient who developed rapid-onset interstitial pneumonia while being treated with cetuximab plus XELOX (oxaliplatin, capecitabine) for metastatic colorectal cancer. A 75-year-old man patient was administered cetuximab plus XELOX regularly. After his cetuximab schedule was adjusted from 1 to 2 weeks, he rapidly developed interstitial pneumonia which led to acute respiratory distress syndrome. Our literature review indicated that, for patients with risk factors, a 2-week regimen of cetuximab might lead to interstitial pneumonia. Clinicians should closely monitor patients for adverse drug reactions to improve drug safety. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Anti-Cancer Drugs Wolters Kluwer Health

Severe interstitial pneumonia caused by cetuximab: a case report and review of the literature

Download PDF
4 pages

Loading next page...
 
/lp/wolters-kluwer-health/severe-interstitial-pneumonia-caused-by-cetuximab-a-case-report-and-rQtLJmXgKf

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
0959-4973
eISSN
1473-5741
DOI
10.1097/cad.0000000000001104
Publisher site
See Article on Publisher Site

Abstract

Cetuximab is an IgG1 chimeric mAb against epidermal growth factor receptor, which can be used for chemotherapy failure or tolerance in patients with epidermal growth factor receptor expressed RAS wild-type metastatic colorectal cancer. We report on a patient who developed rapid-onset interstitial pneumonia while being treated with cetuximab plus XELOX (oxaliplatin, capecitabine) for metastatic colorectal cancer. A 75-year-old man patient was administered cetuximab plus XELOX regularly. After his cetuximab schedule was adjusted from 1 to 2 weeks, he rapidly developed interstitial pneumonia which led to acute respiratory distress syndrome. Our literature review indicated that, for patients with risk factors, a 2-week regimen of cetuximab might lead to interstitial pneumonia. Clinicians should closely monitor patients for adverse drug reactions to improve drug safety.

Journal

Anti-Cancer Drugs – Wolters Kluwer Health

Published: Nov 12, 2021

References

  • Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
    Moosmann, N; Heinemann, V
  • A Phase II study of XELOX and cetuximab as first-line therapy in patients with KRAS wild type metastatic colorectal cancer (FLEET2 study).
    Hazama, S; Maeda, H; Iwamoto, S; Kim, HM; Takemoto, H; Kobayashi, K
  • The biological properties of cetuximab.
    Vincenzi, B; Schiavon, G; Silletta, M; Santini, D; Tonini, G
  • An update of efficacy and safety of cetuximab in metastatic colorectal cancer: a narrative review.
    Fornasier, G; Francescon, S; Baldo, P
  • Consensus statement for the diagnosis and treatment of drug-induced lung injurie.
    Kubo, K; Azuma, A; Kanazawa, M; Kameda, H; Kusumoto, M; Genma, A
  • Cellular and molecular pharmacology of oxaliplatin.
    Raymond, E; Faivre, S; Chaney, S; Woynarowski, J; Cvitkovic, E
  • Literature review and practical aspects on the management of oxaliplatin-associated toxicity.
    Hoff, PM; Saad, ED; Costa, F; Coutinho, AK; Caponero, R; Prolla, G; Gansl, RC
  • Fatal pneumonitis induced by oxaliplatin: description of three cases.
    Pontes, LB; Armentano, DP; Soares, A; Gansl, RC
  • Interstitial lung disease caused by oxaliplatin. An uncommon but not unknown complication.
    Sánchez Cendra, C; Juez Martel, I; Gutierrez Abad, D
  • Prognosis and treatment of FOLFOX therapy related interstitial pneumonia: a plea for multimodal immune modulating therapy in the respiratory insufficient patient.
    De Weerdt, A; Dendooven, A; Snoeckx, A; Pen, J; Lammens, M; Jorens, PG
  • Cetuximab-associated pulmonary toxicity in concurrent chemoradiation for the treatment of a squamous cell carcinoma of the head and neck.
    Mayfield, JD; Mercado, CE; Kaye, FJ; Mendenhall, WM
  • A case of fatal cetuximab-induced interstitial lung disease during the first weeks of treatment.
    Shablak, A; Conn, A
  • Organizing pneumonia secondary to cetuximab in a patient with colorectal.
    AlGhulayqah, A; AlShamsan, B; Bazarbashi, S; Mohammed, S; Mobeireek, A
  • A rare but severe pulmonary side effect of cetuximab in two patients.
    Achermann, Y; Frauenfelder, T; Obrist, S; Zaugg, K; Corti, N; Günthard, HF
  • Incidence and clinical features of drug-induced lung injury in patients with advanced colorectal cancer receiving cetuximab: results of a prospective multicenter registry.
    Satoh, T; Gemma, A; Kudoh, S; Sakai, F; Yamaguchi, K; Watanabe, T
  • Incidence and risk factors of interstitial lung disease of patients with head and neck cancer treated with cetuximab.
    Nakano, K; Seto, A; Sasaki, T; Shimbashi, W; Fukushima, H; Yonekawa, H
  • Understanding the mechanisms of drug-associated interstitial lung disease.
    Higenbottam, T; Kuwano, K; Nemery, B; Fujita, Y
  • FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.
    Brodowicz, T; Ciuleanu, TE; Radosavljevic, D; Shacham-Shmueli, E; Vrbanec, D; Plate, S
  • Multicenter phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: the FLEET study.
    Soda, H; Maeda, H; Hasegawa, J; Takahashi, T; Hazama, S; Fukunaga, M
  • Comparison between biweekly and weekly cetuximab in patients with metastatic colorectal cancer: a meta-analysis.
    Matsuda, A; Yamada, T; Jamjittrong, S; Shinji, S; Ohta, R; Sonoda, H
  • Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors.
    Tan, AR; Moore, DF; Hidalgo, M; Doroshow, JH; Poplin, EA; Goodin, S